FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGES I	N BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average b	urden								
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Mazzo David J				2. Issuer Name and Ticker or Trading Symbol Caladrius Biosciences, Inc. [ CLBS ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
WIGZZO	<u>Daviu s</u>														X	Direc	ctor		10% C	wner	
(Last) (First) (Middle)			3. D	Date of Earliest Transaction (Month/Day/Year)									X		officer (give title elow)		Other (specify below)				
C/O CALADRIUS BIOSCIENCES, INC.				08/	08/17/2015									Chief Executive Officer							
420 LEX	INGTON A	VENUE, SUITE	E 350																		
					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)  NEW YO	ORK N	Y 1	.0170												X	Form	n filed by One	e Reportin	g Pers	on	
-																Form Pers	m filed by More than One Reporting			orting	
(City)	(St	ate) (	Zip)																		
		Tabl	e I - Non	า-Deriva	ative	Sec	curitie	s Acc	quired	, Dis	posed o	f, or	Ben	eficia	ally (	Owne	ed				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution Date,				ies Acquired (A) o Of (D) (Instr. 3, 4			and 5) Secur Benet		cially d Following	6. Owner Form: Di (D) or Ind (I) (Instr.	rect direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A (D	) or )	Price		Transaction(s) (Instr. 3 and 4)				(1130.4)		
Common Stock, par value \$0.001 per share 08/17/2					2015		P		20,000		A	\$1.3	\$1.3961		259,543						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)  2. Conversion of Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  4. Deemed Execution Date if any (Month/Day/Year)		Date, (		of Deriv. Securi (A) or Dispo of (D) (Instr. and 5		rative rities ired r osed )			te	Amount of Securities Underlying Derivative Security (Instr. and 4)  Amour or Numbe of		nstr. 3			9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form Direct or Ind (I) (In	t (D) direct	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

**Explanation of Responses:** 

David J. Mazzo, PhD /s/ Paige

E. Cooperman, Esq., Attorney- 08/18/2015

In-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.